Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025, to all stockholders of ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Amgen announces the launch of Amgen India, a new technology and innovation hub in Hyderabad, that spans approximately 524,000 ...

Amgen ( NASDAQ: AMGN) shares snapped six straight sessions of gains, as the stock ended 3% lower at $306.2 on Wednesday. The ...

Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...